in the news.. · Source: Mossé YP, Laudenslager M, Longo L et al.: Identifi cation of ALK as a...
Transcript of in the news.. · Source: Mossé YP, Laudenslager M, Longo L et al.: Identifi cation of ALK as a...
801
BULLETIN BOARD
ISSN 1475-070810.2217/1475-0708.5.6.801 © 2008 Future Medicine Ltd Therapy (2008) 5(6), 801–805
BULLETIN BOARDHighlighting the latest news and research in therapy
in the news...Adalimumab may be an effective
treatment for JIA
Neuroblastoma: fi rst example of
pediatric cancer oncogene foundpg 802
New research suggests that use of
antipsychotic drugs is associated with a higher risk of stroke pg 802
Approved antihistamine may be used
to treat Alzheimer’s disease pg 803
The careHPV test shows promise as a
primary screening method for cervi-cal cancer prevention in low-resource regions pg 804
Recent drug approvals pg 805
Results from a new study suggest that adali-mumab may be an effective treatment for children suffering from juvenile rheumatoid arthritis. Juvenile rheumatoid arthritis, also known as juvenile idiopathic arthritis, is the most common form of arthritis affecting children. It is an autoimmune disorder characterized by joint swelling, stiffness and occasionally reduced motion. As the tumor necrosis factor has been shown to have a pathogenic function in juvenile rheuma-toid arthritis, the researchers assessed the effectiveness and safety of adalimumab, a TNF inhibitor derived from a fully human monoclonal antibody, in children.
The study included 171 patients aged 4–17 years suffering from active juvenile rheumatoid arthritis. All of the patients had been prescribed nonsteroidal anti-infl am-matory drugs previously. After stratifying the patients according to methotrexate use, they were given 24 mg of adalimumab (brand name Humira®) per square meter of body surface area subcutaneously every other week for a total of 16 weeks. At this point, patients with an American College of Rheumatology Pediatric 30% (ACR Pedi 30) response were randomized to receive either adalimumab or placebo in a double-blind manner every alternate week for up to 32 weeks. This response measure is an indication of the improvement in symptoms of the patient.
In the group not receiving methotrexate, 74% of the patients were found to have an ACR Pedi 30 response at week 16, whereas in the group who had been treated with methotrexate, 94% had an ACR Pedi 30 response at this time point. The patients who had an ACR Pedi 30 response were the ones who had shown an improvement in the symptoms and were eligible for the next phase of the study. The researchers found that amongst the patients who did not receive methotrexate, 43% of those treated with adalimumab and 71% of those given
placebo reported disease fl ares. The latter was the main outcome measure of the study. In the other group consisting of the metho-trexate-treated patients, 37% of those treated with adalimumab experienced disease fl ares, as did 65% of those given placebo. These results were statistically signifi cant.
After 48 weeks of treatment, the scien-tists found that the percentages of patients amongst the methotrexate-treated group, who had an improvement in their symp-toms (as indicated by the ACR Pedi 30, 50 or 70 responses) were signifi cantly greater for those treated with adalimumab compared with those receiving placebo. The differ-ences between those receiving adalimumab and those receiving placebo in the group of non-methotrexate-treated patients were not statistically signifi cant. The response rates were maintained for 104 weeks of treat-ment. A total of 14 serious adverse events, out of which half were serious infections, that could be related to adalimumab were reported in the study.
Owing to insuffi cient sample size and duration, the researchers could not estab-lish the risks for rare adverse events. In addition, they were also unable to identify differences between patients treated with methotrexate and those not receiving it due to insuffi cient power of the study.
“Adalimumab, alone or in combination with methotrexate, appears to be an effi ca-cious option for the treatment of children with polyarticular juvenile rheumatoid arthritis. Responses were sustained through two years of continued treatment,” the authors stated.
Source: Lovell DJ, Ruperto N, Goodman S et al.;
Pediatric Rheumatology Collaborative Study
Group; Pediatric Rheumatology International
Trials Organisation: Adalimumab with or without
methotrexate in juvenile rheumatoid arthritis. N.
Engl. J. Med. 359(8), 810–820 (2008).
Adalimumab may be effective treatment for juvenile rheumatoid
arthritis, report suggests
The autoimmune disorder juvenile rheumatoid arthritis may be effectively treated with the TNF inhibitor adalimumab
Therapy (2008) 5(6)802 future science group
BULLETIN BOARD
Scientists at the Children’s Hospital of Philadelphia, USA, have discovered the group of genetic mutations responsible for the development of the inherited aggressive childhood cancer neuroblas-toma. The mutations have also been implicated in the high-risk form of spo-radic neuroblastoma, the most common type of the disease. Germline mutations in the anaplastic lymphoma kinase (ALK ) gene were detected in several cases of familial neuroblastoma under investigation at the Children’s Hospital, with researchers drawing on data accu-mulated worldwide. This current study also represents the fi rst account of a childhood cancer caused by oncogenic mutations, and helps to further estab-lish ALK as a crucial neuroblastoma oncogene.
“This discovery enables us to offer the fi rst genetic tests to families affected by the inherited form of this disease,” said pediatric oncologist Dr Yael P Mossé, of The Children’s Hospital of Philadelphia, PA, USA, the fi rst author of the study. “Furthermore, because there are already drugs in development that target the same gene in adult cancers, we can soon begin testing those drugs in children with neuroblastoma.”
Neuroblastoma is the most com-mon solid tumor of early childhood, accounting for approximately 8% of all childhood cancers, but is, however, responsible for 15% of all cancer deaths
in children owing to the aggressive nature of the disease.
The current study performed a genome-wide scan of DNA samples from 20 families with familial neuro-blastoma, with the initial identifi cation of a signifi cant predisposition locus at chromosome bands 2p23–24. Further investigation of that region on chromo-some 2 revealed three separate germline missense aberrations in the tyrosine kinase domain of the ALK gene com-mon to eight of the families under observation.
Next, the researchers focused on whether ALK mutations could be somatically acquired in the more common occurrence of noninherited neuro blastoma. Tumor samples from 194 high-risk cases of the sporadic form of the disease were analyzed, and ALK mutations were found in over 12% of cases.
These discoveries thus offer amenable therapeutic drug targets for the inhibi-tion of tumors, and several pharma-ceutical companies are currently devel-oping ALK inhibitors, with one already undergoing early-phase adult clinical trials.
Source: Mossé YP, Laudenslager M, Longo L
et al.: Identifi cation of ALK as a major familial
neuroblastoma predisposition gene. Nature
doi:10.1038/nature07261 (Epub ahead of
print) (2008).
Neuroblastoma: fi rst example of pediatric cancer oncogene found
New research suggests that use of antipsychotic drugs is associated with a higher risk of stroke
A recent study from the London School of Hygiene and Tropical Medicine, UK, has investigated the association between the use of typical and atypical antipsychotic drugs and the incidence of stroke in patients with and with-out dementia. Published in the British Medical Journal, the results suggest that all antipsy-chotics are associated with an increased risk of stroke, and that the risk may be higher in patients receiving atypical antipsychotics com-pared with those receiving typical antipsychot-ics. In addition, people with dementia appear to be at a higher risk of an associated stroke compared with those without dementia.
Participants included in the study were identifi ed with the use of UK-based electronic primary care records of more than 6 million patients from over 400 general practice clin-ics. A total of 6790 patients (905 of whom had received an atypical antipsychotic) with a recorded incident stroke and at least one pre-scription for any antipsychotic drug before the end of 2002 were included in the analysis. At the time of fi rst drug exposure, the median patient age was 80 years and 64% were women.
The results demonstrated that use of any antipsychotic drug was associated with a rate ratio for stroke of 1.73. In addition, the rate ratio for stroke among patients taking typical antipsychotics was 1.69 compared with 2.32 among patients taking atypical anti psychotics. In patients receiving any antipsychotic drug, the rate ratios were 3.50 for those with demen-tia compared with 1.41 for those without dementia
“This implies that the use of antipsychotics might be acceptable in elderly patients without dementia, although as with all treatment choices, a wider consideration of all potential risks and benefi ts would need to be taken into account,” comment the researchers.
Source: Douglas IJ, Smeeth L: Exposure to antipsychot-
ics and risk of stroke: self controlled case series study.
Br. Med. J. (2008) (Epub ahead of print).
About the Bulletin BoardThe Bulletin Board highlights some of the most important events and research in medicine.If you have newsworthy information, please contact:Charlotte Barker, Managing Commissioning Editor, Therapy, Future Medicine Ltd, Unitec House, 2 Albert Place, London N3 1QB, UK; Tel.: +44 (0)20 8371 6090; Fax: +44 (0)20 8343 2313; [email protected]
www.futuremedicine.com 803future science group
BULLETIN BOARD
Approved antihistamine may be used to treat Alzheimer’s disease
Dimebon, a drug once approved as an anti-histamine in Russia, has now been shown to improve cognitive decline in patients with Alzheimer’s disease. Lead author of the study, Dr Rachelle Doody, profes-sor of neurology at the Baylor College of Medicine in Houston, TX, USA, is encouraged by the results.
The study, which was conducted at 11 sites in Russia, enrolled 183 patients with mild-to-moderate Alzheimer’s dis-ease. Patients were randomized to receive either oral dimebon, 20 mg twice-daily or placebo. The effects of dimebon were analyzed over a 12-month period, where patient progress was assessed on fi ve dif-ferent outcomes: thinking and memory
ability, overall function, psychiatric and behavioral symptoms, and ability to per-form daily activities. During this time, the researchers observed a continued improve-ment in patients. “What we saw in the clin-ical trial is that people on the medication continued to improve over time. Those on placebo continued to decline”, said Doody. “Usually at this point in a drug’s develop-ment, we are happy to see improvement in one of the outcome measures, we saw improvement in all fi ve.”
The data suggests that dimebon is safe, well-tolerated and has caused signifi cant improvements in the clinical course of patients suffering from mild-to-moderate Alzheimer’s disease. Currently, the safety,
tolerability and effi cacy of dimebon is being evaluated in an ongoing Phase III study in several international locations, including the USA.
“As we continue research, we hope to replicate these results,” Doody said. “My belief is that this drug will turn out to be useful for Alzheimer’s disease, regardless of the stage of the disease.”
Source: Doody RS, Gavrilova SI, Sano M et al.:
Effect of dimebon on cognition, activities of daily
living, behaviour, and global function in patients
with mild-to-moderate Alzheimer’s disease: a
randomised, double-blind, placebo-controlled
study. Lancet 372(9634), 207–215 (2008).
The careHPV test shows promise as a primary screening method for cervical cancer prevention in
low-resource regionsA new rapid screening test for the human papillomavirus (HPV), created for use in developing countries, has been tested recently on a group of local women in the Shanxi province in eastern China and has been shown to be 90% accurate in detect-ing precancerous cervical disease.
The test in question is called the careHPV, and was designed by Attila Lorincz, a Professor of Molecular Epidemiology at Barts and The London School of Medicine and Dentistry, UK. It can be used to carry out screening in rural areas by personnel with minimal training. The test is able to detect 14 high-risk types of carcinogenic HPV and it can be per-formed in approximately 2.5 h.
Countries in the developed world have the necessary infrastructure to provide cytologic screening, which has led to a 50–80% decrease in mortality. However, to date it has been diffi cult to use cyto-logic screening in low-resource settings;
there have been problems with taking smears and analyzing them correctly.
Research into the development of a rapid, simple and cheap HPV DNA screen-ing test that could be used in rural and low-resource regions was carried out in collabo-ration with the Program for Appropriate Technologies in Health (PATH, Seattle WA, USA) and funded by the Bill and Melinda Gates Foundation.
“The new test needs to be studied in many countries to confi rm its suitability
for cervical cancer screening on the global stage.”
The test is modifi ed from the Hybrid Capture test, the gold-standard routine HPV DNA test, which was created by Lorincz for use in developed countries. It is a signal amplifi cation assay that can be per-formed in a small bench-top work space.
There is no requirement for mains electric-ity or running water. The short assay time of approximately 2.5 h allows testing and clinical follow-up on the same day.
Using the prototype careHPV test, a total of 2388 women between the ages of 30 and 54 years, from the Shanxi province in China, were screened. The sensitivity of the test to detect precancerous cells was found to be 90%. “The clinical performance of my new HPV test in China appears promising – it is based on decades of research and I hope it will be employed widely to save the lives of millions of women. The new test needs to be studied in many countries to confi rm its suitability for cervical cancer screening on the global stage,” commented Lorincz.
Source: Qiao YL, Sellors JW, Eder PS et al.: A new
HPV-DNA test for cervical-cancer screening in
developing regions: a cross-sectional study of clini-
cal accuracy in rural China. Lancet Oncol. (2008)
(Epub ahead of print).
Therapy (2008) 5(6)804 future science group
BULLETIN BOARDR
ecen
t d
rug
ap
pro
vals
et aD
rerutca f
una
Mn
oige
Rn
oitacid
nIe
man ci re
neG
ema
n edarT
app
rove
d
On
colo
gy
Alo
xi®
80
0 2 tsu guA
erachtl aeH nni sle
HAS
Ugniti
mo v dna a esua n decud ni-ypar ehtom eh
Ce
dirolhcor dyh no rteson olaP
Sanc
uso
®G
rani
setr
onPr
even
tion
of
naus
ea a
nd v
omiti
ng in
pat
ient
s re
ceiv
ing
mo
der
atel
y an
d/o
r hi
ghly
em
eto
gen
ic c
hem
othe
rapy
reg
imen
s of
up
to
5 co
nsec
utiv
e da
ys d
urat
ion.
USA
Stra
kan
Inte
rnat
iona
l, Lt
d.Se
ptem
ber
20
08
Vel
cad
e® oh tr
O /g ali
C-n ess naJ
UEa
mole ym elpitl u
m det ae rtn u ylsuoiver Pbi
mo zet roB
Bi
otec
hSe
ptem
ber
20
08
Ont
ak®
80
02 reb
otcO
no ita ropro
C i asiEAS
Ua
m ohpmyl llec-T suo e
natuC
xotitf id nikueli neD
Cep
len
e®8
00 2 r e
botc
Op ro
C tpeCipE
UEa i
mek uel dioley
m e tuc a ht iw stl ud
Ae
di ro lh cor dyh id e
nimatsi
H
Neu
rolo
gy
Cym
balt
a® dna )
ASU( yl liL ilE
UEre
d r osi d yt eixna dezi lar e
neG
enitexolu
DB
oeh
ring
er In
gel
heim
(G
erm
any)
Aug
ust
200
8
Xen
azin
e® ,s la citueca
m rahP kciwts erP
ASU
aerohc s’ notgn it nu
He
ni za nebart eT
Inc.
Aug
ust
200
8
KEP
PRA
XR™
Leve
tirac
etam
Part
ial o
nset
sei
zure
s in
pat
ient
s 16
yea
rs o
f ag
e an
d o
lder
w
ith
epile
psy
USA
UC
B IN
CSe
ptem
ber
20
08
Vim
pat®
Laco
sam
ide
Part
ial-
onse
t se
izur
es w
ith
or w
itho
ut s
econ
dary
gen
eral
izat
ion
in
pati
ents
wit
h ep
ileps
y ag
ed 1
6 ye
ars
and
old
er r e
bmetp eS
BC
UUE
200
8
Vim
pat®
Laco
sam
ide
Ad
d-o
n th
erap
y fo
r th
e tr
eatm
ent
of p
artia
l-on
set
seiz
ures
in p
eopl
e w
ith
epile
psy
who
are
17
year
s an
d o
lder
80
0 2 reb
otcO
BC
UAS
U
Sero
quel
XR
®Q
uet
iapi
ne
fum
arat
eTr
eatm
ent
of b
oth
dep
ress
ive
and
man
ic e
piso
des
ass
oci
ated
wit
h bi
po
lar
diso
rder
USA
Ast
raZe
neca
Oct
ob
er 2
00
8
Car
dio
log
y
Trac
leer
®8
002 tsugu
AdtL noil etc
AU E
n oisn etrepyh lai retr a y ra no
m lup c it amot p
mys yldl iM
nat ne so
B
80
02 tsug uA
ynapmo
C senic ide
M ehTAS
Un oi sn et re
pyh et a red
om-
ot -dli
Meta ry tu B e
n ip idi velC
™ xerp iv elC H
emat
olo
gy
Npl
ate™
Rom
iplo
stim
Trea
tmen
t of
thr
omb
ocy
top
enia
in p
atie
nts
wit
h ch
roni
c im
mun
e (id
iop
athi
c) t
hrom
bo
cyto
pen
ic p
urpu
raU
SAA
mg
en In
cA
ugus
t 20
08
Ko
gen
ate®
Ant
ihem
oph
ilic
fact
or
(rec
ombi
nant
)Ro
utin
e pr
oph
ylax
is in
chi
ldre
n w
ith
hem
oph
ilia
AFD
ABa
yer
Hea
lthC
are
Oct
ob
er 2
00
8
Xar
elto
®Ri
varo
xaba
nPr
even
tion
of
veno
us b
loo
d cl
ots
in a
dult
s un
der
go
ing
elec
tive
hip
or
knee
-rep
lace
men
t su
rger
y.8
002 r e
botc
Or ey aB
UE
Infe
ctio
us
dis
ease
Cef
epim
e in
pl
asti
c co
ntai
ner
Cef
epim
e hy
dro
chlo
ride
Pneu
mon
ia; e
mpi
ric
ther
apy
for
febr
ile n
eutr
op
enic
pat
ient
s;
unco
mpl
icat
ed a
nd c
ompl
icat
ed u
rinar
y tr
act
infe
ctio
ns;
unco
mpl
icat
ed s
kin
and
skin
str
uctu
re in
fect
ions
; and
com
plic
ated
in
tra-
abd
omin
al in
fect
ions
USA
Baxt
er H
ealt
hcar
e C
orp
orat
ion
Aug
ust
200
8
www.futuremedicine.com 805future science group
BULLETIN BOARD
Rec
ent
dru
g a
pp
rova
ls
etaD
reru tcaf
un a
Mn
oige
Rn
oita cid
nIe
man cire
n eG
ema
n edarT
app
rove
d
,slacitu ecamrah P c et o
biTUE
1 -VI
Heni rivartE
™ec ne letnILt
d; J
anss
en-C
ilag
Inte
rnat
iona
l NV
Sept
emb
er
200
8
Prez
ista
® n oitani b
moc V I
H f o tra p sa gni so
d yliad-ec no ro f noi tacid ni dedn apxE
rivanu raD
th
erap
y in
tre
atm
ent-
naïv
e ad
ults
USA
Tib
otec
Pha
rmac
euti
cals
Oct
ob
er 2
00
8
End
ocr
ino
log
y &
met
abo
lism
Nov
olo
g® m
ix
50
/50
Insu
lin a
spar
t pr
otam
ine
reco
mbi
nant
; ins
ulin
asp
art
reco
mbi
nant
Con
tro
l of
hyp
ergl
ycem
ia in
pat
ient
s w
ith
diab
etes
mel
litus
USA
Nov
o N
ordi
sk In
c.A
ugus
t 20
08
Api
dra®
Insu
lin g
lulis
ine
inje
ctio
nIm
prov
e gl
ycem
ic c
ontr
ol i
n ch
ildre
n (4
yea
rs a
nd o
lder
) wit
h di
abet
es m
ellit
usU
SASa
nofi
-ave
ntis
Oct
ob
er 2
00
8
Dia
gn
ost
ics
Adr
evie
w™
Iob
engu
ane
I 123
Det
ecti
on o
f pr
imar
y or
met
asta
tic
pheo
chro
mo
cyto
ma
or
neu
robl
asto
ma
as a
n ad
junc
t to
oth
er d
iagn
ost
ic t
ests
USA
GE
Hea
lthc
are
Sept
emb
er
200
8
AK
-FLU
OR
®
10%
Fluo
resc
ein
sodi
umD
iagn
osti
c fl u
ores
cein
ang
iogr
aphy
or
angi
osc
opy
of
the
retin
a an
d iri
s va
scul
atur
eU
SAA
korn
Inc.
Aug
ust
200
8
AK
-FLU
OR
®
25%
Fluo
resc
ein
sodi
umD
iagn
osti
c fl u
ores
cein
ang
iogr
aphy
or
angi
osc
opy
of
the
retin
a an
d iri
s va
scul
atur
eU
SAA
korn
Inc.
Aug
ust
200
8
Uro
log
y
Rapa
fl8
002 r e
botc
Osla citueca
m rah P n ostaW
ASU
eta tso rp de
gral ne f o tnemtaerT
n iso
doliS
™ o
Oth
er
Cin
ryze
™C
1 In
hibi
tor
(hum
an)
Ad
ole
scen
t an
d ad
ult
pati
ents
wit
h he
redi
tary
ang
ioed
ema
FDA
Lev
Phar
mac
euti
cals
, Inc
.O
cto
ber
20
08
Pirf
enid
one
Idio
path
ic p
ulm
onar
y fi
80
0 2 reb
otcO
cnI ,e nuMretnI
napaJs iso rb
Vap
riso
l®
prem
ixed
in
5% d
extr
ose
Con
ivap
tan
hydr
och
lorid
e in
ject
ion
Euvo
lem
ic a
nd h
yper
vole
mic
hyp
onat
rem
ia in
ho
spit
aliz
ed p
atie
nts
USA
Ast
ella
s Ph
arm
a U
S, In
cO
cto
ber
20
08
Alli
®8
002 re
botc
Oenil
KhtimSo xal
GUE
yti seb
Og
m 06 tatsil r
O
Akt
en™
gel
3.
5%Li
do
cain
e hy
dro
chlo
rid
e o
phth
alm
ic g
elO
cula
r su
rfac
e an
esth
esia
dur
ing
oph
thal
mo
logi
c pr
oce
dure
sU
SAA
korn
Inc.
Oct
ob
er 2
00
8
Ast
epro
® n
asal
sp
ray
Aze
last
ine
hyd
roch
lorid
eRe
lief
of s
ympt
oms
of s
easo
nal a
llerg
ic r
hini
tis in
pat
ient
s 12
yea
rs o
f ag
e an
d o
lder
USA
Med
Poin
te P
harm
aceu
tica
lsO
cto
ber
20
08
LoSe
ason
ique
®Le
vono
rges
trel
/eth
inyl
est
radi
ol
tabl
ets
0.10
/0.0
2 m
g an
d et
hiny
l es
trad
iol t
able
ts 0
.01
mg
Ora
l con
trac
epti
ve f
or t
he p
reve
ntio
n of
pre
gnan
cyU
SABa
rr P
harm
aceu
tica
ls, I
nc.
Oct
ob
er 2
00
8